Biotech & Life SciencesFintechClimate & EnergyManufacturingE-Commerce & MarketplaceCrypto & Web3Media & Entertainment
Pictet's venture capital strategy, primarily through Pictet Alternative Advisors, focuses on thematic private equity investments in high-potential private companies. They target sectors such as healthcare/biotech, technology, and environmental technology, investing in best-in-class venture capital, growth, and private equity funds globally, alongside significant co-investments across various company maturity stages.
Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Average disclosed round size is $91.9M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
$46B
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
 Mainspring Energy, Inc. | Series F | $258M | Apr 2025 |
 Fairmat | Series B | $51.5M | Apr 2025 |
 Taurus SA | Series C | $65M | Feb 2023 |
| LLe Collectionist | Unknown | $60M | Dec 2022 |
 Chainalysis | Series E | $100M | Jun 2021 |
 SOPHiA GENETICS | Series F | $110M | Oct 2020 |
 MUBI | Series A | $15M | Jan 2015 |
 Taurus | Series B | $65M | — |
Top Co-Investors
Credit Suisse2 shared
Temasek Holdings2 shared
Cedar Mundi Ventures2 shared
aMoon1 shared
Hitachi Ventures1 shared
Swisscom Venture1 shared
Endeavour Vision1 shared
Generation Investment Management1 shared
Alychlo1 shared
Eurazeo1 shared
General Catalyst1 shared
Amazon Climate Pledge Fund1 shared
DCVC1 shared
Marunouchi Innovation Partners1 shared
M&G Investments1 shared
Lightrock1 shared
Khosla Ventures1 shared
Gates Frontier1 shared
Highland Europe1 shared
Famille C1 shared
Last updated: 16 April 2026